WASHINGTON, DC
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)INSTITUTE FOR GENE THERAPIES, founded in 2019, is a community nonprofit in the Medical Research sector that reported $1.1M in total revenue in fiscal year 2024. Revenue fell 22% from the prior year — a significant decline worth monitoring. Expenses of $1.2M exceeded revenue, resulting in a 10% operating deficit.
IGT AIMS TO EDUCATE POLICY MAKERS, MEDIA, PATIENTS AND HEALTH CARE PROVIDERS ABOUT THE SCIENCE OF GENE AND CELL THERAPIES, ADVOCATE FOR A MODERNIZED REGULATORY FRAMEWORK THAT ENCOURAGES CURATIVE INNOVATIONS, PROMOTES PATIENT ACCESS, AND CODIFIES TRANSPARENT REIMBURSEMENT PRACTICES FOR THE BETTERMENT OF PATIENTS, FAMILIES AND CAREGIVERS WITH RARE AND COMPLEX MEDICAL CONDITIONS.
IGT ADVOCATES FOR A MODERNIZED REGULATORY AND REIMBURSEMENT FRAMEWORK THAT ENCOURAGES THE DEVELOPMENT OF TRANSFORMATIVE GENE THERAPIES AND PROMOTES PATIENT ACCESS.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $1,093,387 | $1,400,439 | -0.2% |
| Expenses | $1,207,387 | $1,158,630 | +0.0% |
| Net Income | $-114,000 | $241,809 | -1.5% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| ERIK PAULSEN | CHAIRMAN | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| MICHAEL CAPALDI | PRESIDENT | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| KENNETH HODGE | SECRETARY | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| CHRISTOPHER MAY | TREASURER | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | $1,093,387 | $1,207,387 | $875,245 | $-114,000 |
| 2023 | $1,400,439 | $1,158,630 | $846,401 | $241,809 |
| 2022 | $1,325,000 | $1,103,289 | $538,185 | $221,711 |
| 2021 | $1,200,000 | $1,118,949 | $285,097 | $81,051 |
| 2020 | $550,000 | $871,510 | $475,691 | $-321,510 |
| 2019 | $510,000 | $138,823 | $371,177 | $371,177 |
Compare INSTITUTE FOR GENE THERAPIES with other nonprofits in District of Columbia and across the country.